Walgreens Boots Alliance — Q2 2021 Earnings Presentation
36 slides from Walgreens Boots Alliance's earnings presentation, Mar 31, 2021
Slide 1: Fiscal 2021 Second Quarter Results
Fiscal 2021 Second Quarter Results March 31, 2021 © 2021 Walgreens Boots Alliance, Inc. All rights reserved. 1
Slide 2: Safe harbor and non-GAAP
Safe harbor and non-GAAP Cautionary Note Regarding Forward-Looking Statements: Al l s ta tements i n these ma terials and the related presentation that a re not historical i ncluding, without limitation, estimates of a nd goals for future operating, fi na ncial a nd tax performance a nd results, inc
Slide 3: Introduction
Introduction • Excited to be leading WBA ⎯ committing to a deep immersion ⎯ engaging with a talented team ⎯ absorbing the rich culture • Great time to join the organization ⎯ strong 1H financial performance ⎯ vaccine administration provides opportunity to accelerate strategic priorities ⎯ significan
Slide 4: Segment Structure
Segment Structure - United States - International © 2021 Walgreens Boots Alliance, Inc. All rights reserved. 4
Slide 5: New financial reporting structure
New financial reporting structure Continuing Operations United States International Corporate & Other Discontinued operations Boots UK, Republic of Walgreens Ireland & Opticians AllianceRx WP Divested wholesale Corporate costs iA Mexico businesses Chile Boots Thailand ABC income Franchising WBA inve
Slide 6: WBA Financial Performance
WBA Financial Performance © 2021 Walgreens Boots Alliance, Inc. All rights reserved. 6
Slide 7: 2Q financial highlights
2Q financial highlights • Total adjusted EPS $1.40; exceeded expectations ⎯ -8.2% below prior year in constant Fx • Continuing operations adjusted EPS $1.26, -10.8% below prior year in constant Fx ⎯ includes an estimated COVID-19 impact of $0.40 to $0.45 • Strong second quarter performance ⎯ driven
Slide 8: 2Q financial highlights
2Q financial highlights Results, as recast Reported Fx Constant Fx 2Q21 $ in millions (except EPS) B/(W) vs. 2Q20 B/(W) vs. 2Q20 Sales (continuing) $32,779 + 4.6% + 3.5% Operating income GAAP $832 - 26.8% (continuing) Adjusted $1,225 - 22.5% - 22.9% EPS - total GAAP $1.19 + 10.9% Adjusted $1.40 - 7.
Slide 9: First half FY21 financial highlights
First half FY21 financial highlights Results, as recast Reported Fx Constant Fx 1H21 $ in millions (except EPS) B/(W) vs. 1H20 B/(W) vs. 1H20 Sales (continuing) $64,217 + 4.8% + 4.0% Operating income GAAP $298 - 85.5% (continuing) Adjusted $2,422 - 17.2% - 17.6% EPS - total GAAP $0.83 - 58.8% Adjust
Slide 10: United States – financials
United States – financials Continuing operations, as recast $ in millions 2Q21 B/(W) vs. 2Q20 1H21 B/(W) vs. 1H20 Sales $27,344 + 0.4% $54,507 + 2.1% Adj. gross profit $5,704 - 3.2% $11,375 - 2.5% Adj. SG&A % of sales 17.1% - 0.3%p 17.0% + 0.1%p Adj. operating income $1,163 - 18.2% $2,318 - 14.9% 1
Slide 11: United States – pharmacy
United States – pharmacy 2Q 2Q 1H 1H 2Q21 vs. 2Q20 Total Comparable Total Comparable Pharmacy sales + 3.0% + 4.5% + 4.4% + 4.8% Prescriptions - 2.8% - 1.1% - 0.8% + 0.7% • Total prescription growth negatively impacted by store optimization programs -65bps and leap year -60bps • 2Q Rx script comp. pe
Slide 12: United States – retail
United States – retail 2Q 1H 2Q21 vs. 2Q20 Total retail sales - 6.6% - 4.6% Comparable retail sales - 3.5% - 1.7% • Total retail sales growth negatively impacted by store optimization programs -80bps and leap year ~-100bps • 2Q comp. retail sales ex-tobacco & e-cig. -2.7% as COVID-19 continues to im
Slide 13: International – financials
International – financials Continuing operations, as recast Constant Fx Constant Fx $ in millions 2Q21 B/(W) vs. 2Q20 1H21 B/(W) vs. 1H20 Sales $5,425 + 23.9% $9,709 + 16.7% Adj. gross profit $1,078 - 13.4% $2,069 - 11.7% Adj. SG&A % of sales 17.2% + 6.5%p 18.9% + 5.7%p Adj. operating income $146 -
Slide 14: Boots UK – financials
Boots UK – financials 2Q 1H 2Q21 vs. 2Q20 (constant Fx) Pharmacy comp. sales + 3.2% + 2.8% Retail comp. sales - 17.9% - 13.9% • Pharmacy comp. sales impacted by lower demand for scripts, notably in city centers, offset by favorable NHS funding phasing and a partial recovery in services • National UK
Slide 15: Cash flow
Cash flow B/(W) $ in millions 1H21 vs. 1H20 Operating cash flow $2,556 $72 Cash capital expenditure $692 $13 Free cash flow $1,864 $85 • YTD free cash flow grew +4.8% versus prior year • Payment terms and pharmacy inventory optimization driving working capital benefits • FCF continues to benefit fro
Slide 16: Fiscal year 2021 guidance
Fiscal year 2021 guidance Constant Fx continuing ops. adj. EPS growth: mid-to-high single digit • Raising total adj. EPS guidance to mid-to-high single digit growth • Improved outlook reflecting strong 1H & anticipated significant 2H EPS growth Headwinds Tailwinds - Exceptionally weak cold, cough, f
Slide 17: WBA initiatives
WBA initiatives • Majority investment in iA, automated pharmacy solutions company Capital Allocation/ • Alliance Healthcare divestiture on schedule to close before end of FY21 M&A Initiatives • Partial sale of Option Care Health, Inc. investment, $230m proceeds • Launch preparation broadly on track
Slide 18: International initiatives
International initiatives • Boots brand continues to strengthen with UK consumers ⎯ YouGov reputation score at five-year high • Boots.com continues to be a top UK online destination for consumers, sales up +105% in 2Q vs. 2Q20 • Rolled out new No7 counters in more than 100 additional locations, bri
Slide 19: United States initiatives
United States initiatives • Continue to play a key role on the front lines of the pandemic ⎯ >8m vaccinations administered to date; accelerating to >4m vaccines during March ⎯ 59k qualified healthcare associates administering vaccines ⎯ Test & Protect B2B service launched • Modernizing pharmacy oper
Slide 20: United States initiatives
United States initiatives • Find Care app reaching wide audience with ~70m visits in 2Q mostly driven by COVID-19 ⎯ Non COVID-19 visits increased +92% vs. 1Q21 • myWalgreens membership up +41% vs. prior quarter to ~56m members to date ⎯ February NPS +41% higher than prior Balance Rewards loyalty pro
Slide 21: © 2021 Walgreens Boots Alliance, Inc. All rights reserved. © 2020 Walgreens Boots Alliance,
© 2020 Walgreens Boots Alliance, Inc. All rights reserved. © 2021 Walgreens Boots Alliance, Inc. All rights reserved. Refer to safe harbor and non-GAAP on page 2 and endnotes on page 22 Confidential and Proprietary information. For internal use only. 21
Slide 22: Endnotes
Endnotes • Unless otherwise noted, all prior year numbers have been recast for continuing operations. Refer to WBA's Current Report on Form 8-K filed on March 31, 2021. • Please see appendix for reconciliations of non-GAAP financial measures and related disclosures ◦ The company presents certain inf
Slide 23: Appendix
Appendix The information on the following pages provides reconciliations of the supplemental non-GAAP financial measures, as defined under SEC rules, presented in this presentation and discussed on the related conference call to the most directly comparable financial measures calculated and presente
Slide 24: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) NET EARNINGS Three months ended Change vs. 2Q20 Six months ended Change vs. 1H20 February 28, 2021 February 29, 2020 Amount Percent February 28, 2021 Febru
Slide 25: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) NET EARNINGS Three months ended Change vs. 2Q20 Six months ended Change vs. 1H20 February 28, 2021 February 29, 2020 Amount Percent February 28, 2021 Febru
Slide 26: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) DILUTED NET EARNINGS (LOSS) PER SHARE Three months ended Change vs. 2Q20 Six months ended Change vs. 1H20 February 28, 2021 February 29, 2020 Amount Percent February 28,
Slide 27: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) 1 Adjustments to equity earnings (loss) in AmerisourceBergen consist of the Company’s proportionate share of non-GAAP adjustments reported by AmerisourceBergen consisten
Slide 28: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Three months ended February 28, 2021 Walgreens Boots United States1 International Corporate and Other Alliance, Inc. Sales $ 27,344 $ 5,425 $ 10 $ 32,779 G
Slide 29: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Three months ended February 29, 2020 Walgreens Boots United States1 International Corporate and Other Alliance, Inc. Sales $ 27,245 $ 4,091 $ — $ 31,336 Gr
Slide 30: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Six months ended February 28, 2021 Walgreens Boots United States1 International Corporate and Other Alliance, Inc. Sales $ 54,507 $ 9,709 $ — $ 64,217 Gros
Slide 31: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Six months ended February 29, 2020 Walgreens Boots United States1 International Corporate and Other Alliance, Inc. Sales $ 53,377 $ 7,870 $ — $ 61,247 Gros
Slide 32: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) EQUITY EARNINGS (LOSS) IN AMERISOURCEBERGEN Three months ended Six months ended February 28, 2021 February 29, 2020 February 28, 2021 February 29, 2020 Equ
Slide 33: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) ADJUSTED EFFECTIVE TAX RATE Three months ended February 28, 2021 Three months ended February 29, 2020 Earnings before Earnings before income tax Income tax
Slide 34: FREE CASH FLOW
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) FREE CASH FLOW Three months ended Six months ended February 28, 2021 February 29, 2020 February 28, 2021 February 29, 2020 Net cash provided by operating a
Slide 35: Comparable sales methodology change
Comparable sales methodology change 1 Walgreens Boots Alliance, Inc. and Subsidiaries Restatement of Comparable Sales (unaudited) Percent increase (decrease) Three months ended November 30, 2019 Three months ended February 29, 2020 Three months ended May 31, 2020 Three months ended August 31, 2020 T
Slide 36: Comparable sales methodology change
Comparable sales methodology change 1 Walgreens Boots Alliance, Inc. and Subsidiaries Restatement of Comparable Sales (unaudited) Percent increase (decrease) Three months ended November 30, 2018 Three months ended February 28, 2019 Three months ended May 31, 2019 Three months ended August 31, 2019 T
Walgreens Boots Alliance — Q2 2021 Earnings Presentation on 6ix